Align Technology (ALGN) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
4 Feb, 2026Executive summary
Q4 2025 delivered record revenues of $1.048 billion, up 5.3% year-over-year, with Clear Aligner volumes and non-GAAP margins exceeding expectations.
Full year 2025 revenues reached $4.0 billion, up 0.9% year-over-year, with Clear Aligner revenues at $3.2 billion and Systems & Services at $789.6 million.
Clear Aligner case shipments hit a record 2.6 million for the year, with strong growth in EMEA, Latin America, and APAC, and stable performance in North America.
Non-GAAP operating margin for 2025 was 22.7%, the highest since 2021, while GAAP operating margin was 13.5%.
Over 22 million Invisalign patients treated to date, including 6.5 million teens and kids.
Financial highlights
Q4 2025 Clear Aligner revenues were $838.1 million, up 5.5% year-over-year and 4% sequentially; Systems & Services revenues were $209.4 million, up 4.2% year-over-year and 10.3% sequentially.
Q4 2025 non-GAAP gross margin was 72%, up 1.6 points sequentially and 1.2 points year-over-year; GAAP gross margin was 65.3%.
Q4 2025 non-GAAP operating margin was 26.1%, up 2.3 points sequentially and 3 points year-over-year; GAAP operating margin was 14.8%.
Q4 2025 non-GAAP EPS was $3.29, up $0.68 sequentially and $0.85 year-over-year; GAAP EPS was $1.89.
Cash and cash equivalents at year-end were $1.095 billion; free cash flow for 2025 was $490.8 million.
Outlook and guidance
Q1 2026 revenue expected between $1.01–$1.03 billion, up 3–5% year-over-year; Clear Aligner volume expected to grow mid-single digits year-over-year.
Q1 2026 GAAP operating margin expected at 12.4–12.8%; non-GAAP margin around 19.5%.
Full year 2026 revenue growth projected at 3–4% year-over-year; Clear Aligner volume growth mid-single digits; GAAP operating margin slightly below 18%, non-GAAP margin around 23.7%.
Capital expenditures for 2026 expected at $125–$150 million.
Latest events from Align Technology
- Broad-based growth, strong DSO performance, and stable outlook drive confidence for 2026.ALGN
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Strong growth in Europe and APAC, with product innovation and efficiency boosting margins.ALGN
Leerink Global Healthcare Conference 202610 Mar 2026 - Digital dentistry expansion, AI-driven innovation, and global growth drive strong financial outlook.ALGN
Investor Day 20253 Feb 2026 - Q2 2024 revenue up 2.6% to $1.03B; margin pressured by FX, mix, and legal settlement.ALGN
Q2 20243 Feb 2026 - Q1 2024 growth fueled by AI, 3D printing, and new digital orthodontic products.ALGN
The 44th Annual William Blair Growth Stock Conference31 Jan 2026 - Raised guidance and new products drive growth, margin expansion, and digital adoption.ALGN
Jefferies Global Healthcare Conference31 Jan 2026 - Stable market, teen growth, new products, and flexible strategies drive future expansion.ALGN
Baird's 2024 Global Healthcare Conference21 Jan 2026 - Q3 revenue rose 1.8% year-over-year to $977.9M; restructuring and $275M buyback announced.ALGN
Q3 202419 Jan 2026 - Growth investments, digital innovation, and global expansion drive recovery and future margin gains.ALGN
UBS Global Healthcare Conference 202414 Jan 2026